Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.31B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.67M
Average 3.00M
OCUL Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Ocular Therapeutix, Inc.NASDAQ: OCUL
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $88.61M (cash outflow) rose 38.3% year over year, behind the +50.7% change in trailing-twelve-month net income. Sequentially, it rose 37.1% from the prior quarter. Over 3 fiscal years it compounded at +55.3% a year.
Context
- Net income amounted to 513.2% of revenue in FY2025, up 209.5 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$298.01M (+12.1%) for the fiscal year ending Dec 2026, a slowdown from the +37.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$88.61M+37.1% QoQ
- Last fiscal yearDec 2025
- -$265.94M+37.4% YoY
- LTMMar 2026
- -$290.5M+50.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +38.3% | +31.5% | -6.8 pp |
| 1 year | +37.4% | +12.1% | -25.4 pp |
| 3-year CAGR | +55.3% | +3.8% | -51.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (265.94M) USD
- Year-over-year change
- -37.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (265.94M) | -37.4% |
| FY2024 | 2024-12-31 | (193.51M) | -139.7% |
| FY2023 | 2023-12-31 | (80.74M) | -13.7% |
| FY2022 | 2022-12-31 | (71.04M) | -984.1% |
| FY2021 | 2021-12-31 | (6.55M) | — |
Net Income vs competitors
How OCUL compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +50.7% is the 3rd highest of 10, against a peer median of -8.3%.
- Net income amounts to 558.2% of revenue for OCUL, versus a peer median of 818.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $290.5M USD | +50.7% | +55.3% | 558.2% | |
| LTM Mar 2026 | $271.6M USD | +85.0% | +31.4% | 3566.6% | |
| LTM Sep 2026 | $246.76M USD | +13.5% | -11.7% | — | |
| LTM Jun 2026 | $188.05M USD | +102.7% | +10.5% | 30.7% | |
| LTM Jun 2026 | $167M USD | -36.5% | — | 3.1% | |
| LTM Mar 2026 | CHF 94.54M CHF | -8.3% | +34.7% | 18758.0% | |
| LTM Mar 2026 | $71.67M USD | +24.7% | -7.9% | 1605.2% | |
| LTM Mar 2026 | $60.96M USD | -388.6% | -1.9% | 18297.5% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $39.87M USD | — | — | — |
| LTM Apr 2026 | $21.03M USD | -70.4% | — | 7.2% | |
| LTM Mar 2026 | $14.96M USD | -31.0% | -28.5% | 5.6% | |
| Peer median (excluding OCUL) | — | -8.3% | -1.9% | 818.0% | |
Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.98M | 16.96M | 17.83M | 33.11M | 43.18M |
| Change in Working Capital | (2.9M) | 1.35M | (7.41M) | (10.23M) | 7.71M |
| Accounts Receivables | (8.88M) | (190K) | (4.85M) | (6.21M) | 1.74M |
| Inventory | (49K) | (724K) | (331K) | (735K) | (524K) |
| Accounts Payables | 1.8M | (621K) | 583K | (318K) | (887K) |
| Other Working Capital | 4.24M | 2.88M | (2.81M) | (2.97M) | 7.38M |
| Other Non-Cash Items | (73.49M) | (8.99M) | (2.9M) | 32.16M | 5.84M |
| Operating Cash Flow | (65.55M) | (59.6M) | (70.23M) | (134.68M) | (204.88M) |
| Capital Expenditures | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (12.01M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 130K |
| Investing Cash Flow | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (11.88M) |
| Debt Repayment | (445K) | 0 | 56.35M | 316.35M | 0 |
| Common Stock Issued | 985K | 940K | 118.11M | 316.35M | 561.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.31M | 514K | (4.63M) | (300.6M) | 0 |
| Financing Cash Flow | 2.85M | 1.45M | 169.83M | 332.11M | 561.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (63.89M) | (61.86M) | 93.51M | 196.15M | 344.96M |
| Free Cash Flow | (66.74M) | (63.32M) | (76.32M) | (135.97M) | (216.89M) |
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.